AxoGen to Participate at 71st Annual American Society for Surgery of the Hand Meeting

ALACHUA, Fla., Sept. 15, 2016 (GLOBE NEWSWIRE) — AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the 71st Annual American Society for Surgery of the Hand Meeting taking place in Austin, Texas from September 29 – October 1, 2016.

AxoGen will sponsor several special programs that support peripheral nerve education and awareness, including the Hand Fellows pre-course program, the ‘Women in Hand Surgery’ event and a surgeon led symposium – ‘Tackling Challenges in Nerve Repair: A Case-Based Discussion’. AxoGen’s full portfolio of nerve repair and assessment products will be featured at ASSH Booth #526.

In addition to our education and awareness efforts, the most recent data from the RANGER® Registry, will be presented in the scientific session.  The presentation from the RANGER Registry investigators will provide further insight into the role of Avance® Nerve Graft in the reconstruction of upper extremity nerve injuries.

“We are excited to see peripheral nerve repair take such a prominent role in this year’s conference with 30 separate presentations,” stated Karen Zaderej, AxoGen’s President and Chief Executive Officer. “Hand surgeons are often faced with challenging nerve injuries and we are pleased to provide scientific data and clinical discussions in support of the role of AxoGen’s portfolio in nerve repair.”

AxoGen will also be hosting a Nerve Repair Discussion Event for the investment community on Wednesday, September 28, preceding the ASSH Meeting. The Event will include the presentation of clinical data from clinical thought leaders and a discussion of peripheral nerve repair focusing on surgeon adoption, development of treatment algorithms, and the growing body of clinical evidence.

Key AxoGen sponsored nerve related presentation details for the ASSH Meeting are as follows:

Friday, September 30, 2016
AxoGen Breakfast Symposium: Tackling Challenges in Nerve Repair: A Case-Based Discussion
Invited Faculty: Gregory M. Buncke, MD, Fraser Leversedge, MD, Peter J. Evans, MD, PhD

RANGER® Registry Data Presentation
Can Processed Nerve Allografts be used to Repair Nerve Injuries Greater than 4 cm for the Return of Critical Function in the Upper Extremity
Authors: Bauback Safa, MD, Jozef Zoldos, MD, Timothy Niacaris, MD, PhD, Leon Nesti, MD, PhD, Jason Ko, MD, Gregory M. Buncke, MD

Details for the AxoGen Nerve Repair Discussion Event for the investment community preceding the ASSH Meeting are as follows:

Wednesday, September 28, 2016
AxoGen Nerve Repair Discussion Event
Location: Getaway Motor Club; 3700 Thompson St., Austin, Texas 78702
Time: 3:30pm to 6:30pm CDT
Participating surgeons: Ivica Ducic, MD PhD, Bauback Safa, MD FACS, Peter Evans, MD PhD FRCSC
Note that this event is an interactive discussion of nerve repair and will not be webcast. Investors who are interested in attending the event can register by email to AxoGenEvents@troutgroup.com.   

About the RANGER® Study
The RANGER® Study, A Multicenter Retrospective Study of Avance® Nerve Graft Utilization Evaluations and Outcomes in Peripheral Nerve Injury Repair is an active, multicenter clinical database with 18 contributing centers designed to continuously monitor and collect injury, repair, safety and outcomes data for peripheral nerve injuries repaired with processed nerve allograft (Avance® Nerve Graft), nerve autograft and synthetic tubes. As of July 2016, the study included more than 900 nerve repairs enrolled across 18 centers and 48 surgeons. The RANGER® Study is an AxoGen sponsored ongoing open label registry study. Each patient outcome is dependent upon the nature and extent of nerve loss or damage, timing between nerve loss and repair and the natural course of the patient’s recovery. Results presented at the ASSH meeting may not represent typical clinical outcomes for individual patients.

About ASSH 2016
The American Society for Surgery of the Hand is the oldest and most prestigious medical society dedicated to the hand and upper extremity. Its mission is to advance the science and practice of hand and upper extremity surgery through education, research and advocacy on behalf of patients and practitioners. For more information, please visit https://www.assh.org/.

About AxoGen
AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen’s portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com

The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com